In vitro modulation of MMP-2 and MMP-9 in pediatric human sarcoma cell lines by cytokines, inducers and inhibitors

Roomi,M.  W.; Kalinovsky,T.; Rath,M.; Niedzwiecki,A.

doi:10.3892/ijo.2013.2159

In vitro modulation of MMP-2 and MMP-9 in pediatric human sarcoma cell lines by cytokines, inducers and inhibitors

Authors:
- M. W. Roomi
- T. Kalinovsky
- M. Rath
- A. Niedzwiecki
View Affiliations

Affiliations: Dr Rath Research Institute, Santa Clara, CA 95050, USA
Published online on: October 31, 2013 https://doi.org/10.3892/ijo.2013.2159
Pages: 27-34
Copyright: © Roomi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The highly aggressive pediatric sarcomas are characterized by high levels of matrix metalloproteinase (MMP)-2 and MMP-9, which play crucial roles in tumor invasion and metastasis by degradation of the extracellular membrane leading to cancer cell spread to distal organs. We examined the effects of cytokines, mitogens, inducers and inhibitors on MMP-2 and -9 expression in osteosarcoma (U2OS) and rhabdomyosarcoma (RD). The selected compounds included natural cytokines and growth factors, as well as chemical compounds applied in therapy of sarcoma and natural compounds that have demonstrated anticancer therapeutic potential. These cell lines were cultured in their respective media to near confluence and the cells were washed with PBS and incubated in serum-free medium with various concentrations of several cytokines, mitogens and inhibitors. After 24 h the media were removed and analyzed for MMP-2 and -9 by gelatinase zymography and quantitated by densitometry. Osteosarcoma and rhabdomyosarcoma showed bands corresponding to MMP-2 and -9 with dose-dependent enhancement of MMP-9 with phorbol 12-myristate 13-acetate (PMA) treatment. Tumor necrosis factor-α, interleukin-1β and LPS enhanced osteosarcoma U2OS MMP-9 secretion but had no effect on MMP-2 secretion. Tumor necrosis factor-α stimulated rhabdomyosarcoma MMP-2 expression, but had no effect on MMP-9 secretion. Doxycycline, epigallocatechin gallate, nutrient mixture (NM), actinomycin-D, cyclohexamide, retinoic acid and dexamethasone inhibited MMP-2 and -9 in U2OS osteosarcoma cells. PMA-treated RD cells showed dose-response inhibition of MMP-9 by doxycycline and epigallocatechin gallate and both MMPs by NM. Dexamethasone and actinomycin-D showed inhibition of MMP-2 secretion of RD cells. Our results show that cytokines, mitogens and inducers show variable upregulation of U2OS osteosarcoma and RD rhabdomyosarcoma MMP-2 and -9 secretion, and inhibitors demonstrate downregulation under stimulatory conditions, suggesting the application of these agents for the development of effective therapies in pediatric sarcomas.

View Figures

View References

1.	National Institute of Health: PubMed Health: Osteosarcoma. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002616/. Accessed March 18, 2013. Last revised 10/2012.
2.	Kaste SC, Pratt CB, Cain AM, Jones-Wallace DJ and Rao BN: Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer. 86:1602–1608. 1999. View Article : Google Scholar : PubMed/NCBI
3.	American Cancer Society: Osteosarcoma: What are the survival rates for osteosarcoma? http://www.cancer.org/cancer/osteosarcoma/detailedguide/osteosarcoma-survival-rates. Accessed March 18, 2013. Last revised 01/17/2013.
4.	National Cancer Institute: Childhood Soft Tissue Sarcoma Treatment (PDQ®). http://www.cancer.gov/cancertopics/pdq/treatment/child-soft-tissue-sarcoma/HealthProfessional/. Accessed March 18, 2013. Last updated 12/3/2012.
5.	Patham DM: Pathologic classification of rhabdomyosarcoma and correlations with molecular studies. Med Pathol. 14:506–514. 2001. View Article : Google Scholar
6.	Mandell L, Ghavinni F, LaQuaglia M and Exelby P: Prognostic significance of regional lymph node involvements in childhood extremity rhabdomyosarcoma. Med Pediatr Oncol. 18:466–471. 1990. View Article : Google Scholar : PubMed/NCBI
7.	Koscielniak E, Rodary C, Flamant F, Carli M, Treuner J, Pinkerton CR and Grono P: Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. Med Pediatr Oncol. 20:209–214. 1992. View Article : Google Scholar : PubMed/NCBI
8.	Benassi MS, Gamberi G, Magagnoli G, Molendini L, Ragazzini P, Merli M, Chiesa F, Balladelli A, Manfrini M, Bertoni F, Mercri M and Picci P: Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol. 12:75–80. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
10.	Liotta LA, Tryggvason K, Garbisa A, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 284:67–68. 1980. View Article : Google Scholar : PubMed/NCBI
11.	Stetler-Stevenson WG: The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin North Am. 10:383–392. 2001.PubMed/NCBI
12.	Stetler-Stevenson WG: Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303. 1990. View Article : Google Scholar : PubMed/NCBI
13.	Sato T, Sakai T, Noguchi Y, Takta M, Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol. 92:47–56. 2004. View Article : Google Scholar
14.	Pyke C, Kristensen P, Ralfkiaer E, Gröndahl-Hansen J, Eriksen J, Blasi F and Danø K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 138:1059–1067. 1991.PubMed/NCBI
15.	Harvey P, Clark IM, Jourand MC, Warn RM and Edwards DR: Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metal-loproteinases. Br J Cancer. 83:1147–1153. 2000. View Article : Google Scholar : PubMed/NCBI
16.	Liu Z, Ivanoff A and Klominek J: Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int J Cancer. 91:638–643. 2001. View Article : Google Scholar : PubMed/NCBI
17.	Vincent MP, White LA, Schroen DJ, Benbow U and Brinckerhoff CE: Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription and mRNA stability. Crit Rev Eukaryot Gene Expr. 6:391–411. 1996. View Article : Google Scholar : PubMed/NCBI
18.	Rutkowski P, Kaminska J, Kowalska M, Ruka W and Steffen J: Cytokine and cytokine receptor serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer. 100:463–471. 2002. View Article : Google Scholar
19.	Himelstein BP, Asada N, Carlton MR and Collins MH: Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med Pediatr Oncol. 31:471–474. 1998. View Article : Google Scholar : PubMed/NCBI
20.	Ferrari C, Benassi S, Ponticelli F, Gamberi G, Ragazzini P, Pazzaglia L, Balladelli A, Bertoni F and Picci P: Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1–16 years. Acta Orthop Scand. 75:487–491. 2004.PubMed/NCBI
21.	Bjornland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O and Maelandsmo GM: Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res. 127:151–156. 2005. View Article : Google Scholar : PubMed/NCBI
22.	Roebuck MM, Helliwell TR, Chaudhry IH, Kalogrianitis S, Carter S, Kemp G, Ritchie DA, Jane MJ and Frostick SP: Matrix metalloproteinase expression is related to angiogenesis and histologic grade in spindle cell soft tissue neoplasms of the extremities. Am J Clin Pathol. 123:405–414. 2005. View Article : Google Scholar : PubMed/NCBI
23.	Diomedi-Carnassei F, Boldrini R, Rava L, Donfrancesco A, Boglino C, Messina E, Dominici C and Callea F: Different patterns of matrix metalloproteinase expression in alveolar versus embryonal rhabdomyosarcoma. J Pediatr Surg. 39:1673–1679. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Ray JM and Stetler-Stevenson WG: The role of matrix metal-loproteinase and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J. 7:2062–2072. 1994.PubMed/NCBI
25.	Apodaca G, Rutka JT, Bouhana K, Berens ME, Giblin JR, Rosenblum ML, McKerrow JH and Banda MJ: Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res. 50:2322–2329. 1990.PubMed/NCBI
26.	Linder C, Linder S, Munck-Wickland E and Strander H: Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res. 18(3B): 2063–2068. 1998.PubMed/NCBI
27.	Graeven U, Andre N, Achilles E, Zornig C and Schmeigel W: Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol. 125:577–581. 1999. View Article : Google Scholar : PubMed/NCBI
28.	Rutkowski P, Kaminska J, Kowalska M, Ruka W and Steffen J: Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol. 84:151–159. 2003. View Article : Google Scholar : PubMed/NCBI
29.	Niedzwiecki A, Roomi MW, Kalinovsky T and Rath M: Micronutrient synergy - a new tool in effective control of metastasis and other key mechanisms of cancer. Cancer Metastasis Rev. 29:529–543. 2010. View Article : Google Scholar : PubMed/NCBI
30.	Roomi MW, Monterrey JC, Kalinovsky T, Niedzwiecki A and Rath M: Inhibition of invasion and MMPs by a nutrient mixture in human cancer cell lines: a correlation study. Exp Oncol. 32:243–248. 2010.PubMed/NCBI
31.	Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines. Oncol Rep. 24:747–757. 2010.PubMed/NCBI
32.	Rath M and Pauling L: Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic analogs. Orthomolecular Med. 7:17–23. 1992.
33.	Sun Z, Chen YH, Wang P, Zhang J, Gurewich V, Zhang P and Liu JN: The blockage of high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochem Biophys Acta. 1596:182–192. 2002.PubMed/NCBI
34.	Valcic S, Timmermann BN, Alberts DS, Wachter GA, Krutzsch M, Wymer J and Guillen JM: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs. 7:461–468. 1996. View Article : Google Scholar : PubMed/NCBI
35.	Mukhtar H and Ahmed N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr. 71:S1698–S1702. 2000.PubMed/NCBI
36.	Yang GY, Liao J, Kim K, Yurtow EJ and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis. 19:611–616. 1998. View Article : Google Scholar : PubMed/NCBI
37.	Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H and Shimikawa R: Effect of (-) epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett. 65:51–54. 1992. View Article : Google Scholar : PubMed/NCBI
38.	Hara Y: Green Tea: Health Benefits and Applications. Marcel Dekker; New York, NY: 2001, View Article : Google Scholar
39.	Kawakami S, Kageyama Y, Fujii Y, Kihara K and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion and MMP 9 production of T24 human bladder cancer cells. Anticancer Res. 21:213–219. 2001.PubMed/NCBI
40.	Morini M, Cai T, Aluigi MG, Noonan DM, Masiello L, De Floro S, D'Agostinin F, Albini A and Fassima G: The role of the thiol N-acetyl cysteine in the prevention of tumor invasion and angiogenesis. Int J Biol Markers. 14:268–271. 1999.PubMed/NCBI
41.	Yoon SO, Kim MM and Chung AS: Inhibitory effects of selenite on invasion of HT 1080 tumor cells. J Biol Chem. 276:20085–20092. 2001. View Article : Google Scholar : PubMed/NCBI
42.	Naidu KA, Karl RC and Coppola D: Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of insulin-like growth factor 1 receptor. Dig Dis Sci. 48:230–237. 2003. View Article : Google Scholar
43.	Anthony HM and Schorah CJ: Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer. 46:354–367. 1982. View Article : Google Scholar : PubMed/NCBI
44.	Maramag C, Menon M, Balaji KC, Reddy PG and Laxmanan S: Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability and DNA synthesis. Prostate. 32:188–195. 1997. View Article : Google Scholar : PubMed/NCBI
45.	Koh WS, Lee SJ, Lee H, Park C, Park MH, Kim WS, Yoon SS, Park K, Hong SI, Chung MH and Park CH: Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines. Anticancer Res. 8:2487–2493. 1998.PubMed/NCBI
46.	Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA. 102:13604–13609. 2005. View Article : Google Scholar
47.	Nunez C, Ortiz de Apodaca Y and Ruiz A: Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of consumption of food with an elevated content of this vitamin. Nutr Hosp. 10:368–372. 1995.PubMed/NCBI
48.	Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C) improves the antineo-plastic activity of doxorubicin, cisplatin and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 103:183–189. 1996. View Article : Google Scholar : PubMed/NCBI
49.	Cooke JP and Dzau VJ: Nitric oxide synthase: Role in the genesis of vascular disease. Annu Rev Med. 48:489–509. 1997. View Article : Google Scholar : PubMed/NCBI